Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
about
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malariaClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyDoravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Efavirenz in the therapy of HIV infection.Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteersQuality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, UgandaClinical management of HIV drug resistance.Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patientsPharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.Atazanavir for the treatment of human immunodeficiency virus infection.Drug interactions in the management of HIV infection.Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.Safety of lopinavir/ritonavir for the treatment of HIV-infection.Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Treatment strategies for highly treatment-experienced HIV-infected patients.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patientsPopulation pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapySteady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.Factors influencing lopinavir and atazanavir plasma concentration.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Safety of pharmacoenhancers for HIV therapy.Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
P2860
Q24538763-2BEA1DC9-F77E-4FBD-9599-27485AD76515Q26771182-FBC55CF3-159F-4633-BC77-6B4E53018A4EQ30373063-E6333EF1-7DD0-4676-A7CF-DAAFF00679D3Q33400092-49BAF9A7-5A7E-4FD8-9494-5FD431AAFE9DQ33559216-4070B16B-CE31-4BD4-81DE-A8CAD5E44C4EQ33607011-3C94FCB4-94A8-402B-AAE9-565A882AE0D9Q33769950-09290B96-50EE-4892-8E6A-D30BC76EFF89Q33962762-F2DB1C53-DBCF-4CB2-8827-BADCD1D1EE2DQ33962854-174E2E6E-6F6C-46FF-BFD2-1589F8395B62Q34114808-994D1569-6B06-4B4A-A1A3-2C434AEDD46AQ35154032-AA4FBCED-E636-4E45-B4C0-9ECCEC2351BBQ35261045-E670A56A-1C3D-4560-BF68-27E4E1FBB5C9Q35826931-7CDAC833-0C38-445F-8907-AA0B67DE45B4Q35827093-893F119A-1535-4D2D-8595-902D52992341Q35894312-02704F98-ECAC-42AF-B50C-3B361E539AFFQ35917140-D9F83E8B-01D0-4E69-942D-0A36ED4E21F2Q35976835-68BEC74B-06DF-41E1-98A9-F8817EDC7795Q36066083-4192288C-A86D-4B26-9E93-D41BED7C9B02Q36111218-996410B8-8DAF-4744-A737-09A6E3BC00D6Q36150530-83C36214-61F8-4945-8115-82601239F110Q36222013-186B0B56-4DD3-4F13-BF3D-6F66F85E4018Q36278090-22DC4E46-43BB-4B87-8A2D-658415189BD5Q36376533-FF00F502-8BBD-4B6C-ADE8-D046F9D4C024Q36544977-2595BA93-044F-4446-83DA-E9764D4CF62CQ36727919-0D8E3250-308F-4239-8165-1D59252AFD48Q36870827-6DFCC7F7-91B8-4AA6-A7F3-2E77DFE3575DQ37036468-5E0472EB-7BB7-49DD-B489-AD83B5BDF14FQ37204267-39BFF5C0-5B15-483A-B831-0955ABC0E7F7Q37204276-3AB58578-AEF5-4A7A-B99C-DD5A2AFCE06AQ37371323-38879E90-AAF9-4898-9786-A6F3A65A901DQ37409968-4814FDFA-C458-48D3-8411-E495642EC91FQ37476403-5AF44AC4-1FD4-41D9-BA3A-B844A7A8E033Q37600844-434204BD-6A79-4C0C-A2B5-4B4050AD6D1DQ37835819-95041172-3BDD-4647-9D24-F82BE81BE540Q38057371-446435C9-92E2-403F-9F81-0A4895E0D348Q39705689-889BD8EE-28E6-421B-878F-A9F6E36694BAQ40131713-E8258249-6873-4FA6-93BA-B37B185B14B4Q40903070-124FE980-935F-4756-AC04-418E0FA95AB9Q41269323-F6175347-9845-43E9-BF66-A8D6A3377E9EQ41902281-AFEFC7B6-7725-4977-96C8-09F1CDEB8B89
P2860
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@ast
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@en
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@nl
type
label
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@ast
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@en
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@nl
prefLabel
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@ast
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@en
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@nl
P2093
P2860
P1476
Pharmacokinetic-pharmacodynami ...... iency virus-infected patients.
@en
P2093
Barry Bernstein
Bruce Richards
Cheryl Foit
Dale J Kempf
Eugene Sun
G Richard Granneman
Jeffrey Isaacson
Karen Rynkiewicz
Martin King
P2860
P304
P356
10.1128/AAC.47.1.350-359.2003
P407
P577
2003-01-01T00:00:00Z